Stryker (NYSE:SYK) Receives Buy Rating from Citigroup

Stryker (NYSE:SYK)‘s stock had its “buy” rating reissued by stock analysts at Citigroup in a report released on Wednesday, MarketBeat.com reports. They currently have a $450.00 price target on the medical technology company’s stock. Citigroup’s price target indicates a potential upside of 15.22% from the stock’s previous close.

A number of other research analysts also recently issued reports on SYK. The Goldman Sachs Group boosted their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Tuesday. BTIG Research increased their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Evercore ISI increased their price target on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Stock Up 0.7 %

Shares of Stryker stock opened at $390.57 on Wednesday. The business has a fifty day simple moving average of $378.78 and a 200 day simple moving average of $370.22. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $149.03 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. Stryker has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. Research analysts predict that Stryker will post 13.47 EPS for the current year.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

Several large investors have recently added to or reduced their stakes in the stock. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter worth approximately $25,000. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter valued at approximately $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.